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Abstract 1 
La/SS-B (or La) is a 48 kDa RNA-binding protein and an autoantigen in autoimmune 2 
disorders such as systemic lupus erythematosus (SLE) and Sjögren’s syndrome 3 
(SS). La involvement in regulating the type I interferon (IFN) response is 4 
controversial - acting through both positive and negative regulatory mechanisms; 5 
inhibiting the IFN response and enhancing viral growth, or directly inhibiting viral 6 
replication. We therefore sought to clarify how La regulates IFN production in 7 
response to viral infection. ShRNA knockdown of La in HEK 293T cells increased 8 
Sendai virus infection efficiency, decreased IFN-β, IFN-λ1, and interferon-stimulated 9 
chemokine gene expression. In addition, knockdown attenuated CCL-5 and IFN-λ1 10 
secretion. Thus, La has a positive role in enhancing type I and type III IFN 11 
production. Mechanistically we show that La directly binds RIG-I and have mapped 12 
this interaction to the CARD domains of RIG-I and the N terminal domain of La. In 13 
addition, we showed that this interaction is induced following RIG-I activation and 14 
that overexpression of La enhances RIG-I-ligand binding. Together, our results 15 
demonstrate a novel role for La in mediating RIG-I-driven responses downstream of 16 
viral RNA detection, ultimately leading to enhanced type I and III IFN production and 17 
positive regulation of the anti-viral response. 18 
 19 
  20 
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Introduction 1 
Host viral detection systems rely mostly on recognition of viral nucleic acids by 2 
pattern recognition receptors (PRRs) including, RNA and DNA-sensing Toll-like 3 
receptors (TLR-3, -7, -8, -9), DNA receptors (DAI, AIM2, IFI16, DDX41) and RIG-I-4 
like receptors (RLRs).  RIG-I is an essential type I and type III IFN-inducing receptor 5 
required for the detection of negative-sense single stranded RNA viruses such 6 
Sendai virus, a member of the Paramyxoviridae family, in addition to Rhabdoviridae 7 
and Orthomyxoviridae family members 1 2,3. Upon recognition of pathogenic RNA, an 8 
ATP-dependent conformational change is triggered in RIG-I exposing the activatory 9 
CARD domains. This allows interaction between the second CARD domain of the 10 
receptor and the CARD domain of downstream mitochondrial-associated adaptor, 11 
IPS-1 4-6. This interaction leads to assembly and activation of downstream IKK-12 
related kinases TBK-1 and IKK-ε, that subsequently phosphorylate IRF-3 and IRF-7 13 
7,8. This ultimately results in transcriptional induction of both type I and type III IFNs, 14 
which in turn leads to robust expression of IFN-stimulated genes (ISGs) 9,10.  15 
Type I IFNs, including IFN-α, -β, -ω, -κ and -ɛ, act on cells via binding to the IFN-16 
α receptor (IFNαR), comprised of an IFNαR1 and IFNαR2 heterodimer 11,12. Type I 17 
IFN synthesis occurs in virtually all cell types downstream of anti-viral PRR 18 
recognition of viral RNA/DNA. Once secreted by the virally-infected cell, type I IFNs 19 
bind and activate IFNαR, leading to induction of interferon stimulated genes (ISGs) 20 
through activation of JAK1 and Tyk2, followed by phosphorylation of signal-21 
transducing activators of transcription (STAT) proteins STAT1 and STAT2 13-16. 22 
ISGs, including RIG-I, TLR-3, OAS1 and OAS2, are expressed following 23 
STAT1/STAT2 activation, leading to the inhibition of transcription and translation of 24 
viral proteins 17,18, along with induction and synthesis of MHC class I expression. 25 
This makes the cell more susceptible to CD8+ cytotoxic T cells 19,20, activates NK 26 
cells which selectively kill virus-infected cells 21,22, and leads to maturation of DCs 23 27 
and B cell responses 20,24.   28 
 Functional members of the Type III IFN family, including IFN-λ1 (IL-29), IFN-29 
λ2 (IL-28A) and IFN-λ3 (IL-28B),  are induced downstream of TLR-3 and RLR 30 
signalling 25,26 but signal through an independent cell-surface receptor complex, 31 
consisting of IL10R2 (also called CRF2-4) and IFN-λR1 (also called IL-28RA) 27,28. 32 
While the type I IFN receptor is ubiquitously expressed, the expression of the IFN-33 
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λR1 component of the type III IFN receptor complex appears to be more limited and 1 
restricted to cells of epithelial origin, plasmacytoid DCs, macrophages, monocyte-2 
derived DCs and intra-hepatic natural killer cells (NKs) 29. Upon type III IFN binding 3 
to the receptor, a signal transduction cascade ensues involving activation of JAK1, 4 
JAK2 and Tyk2, followed by STATs activation and ISG expression, almost identical 5 
to that induced by type I IFN receptor 27,30.  6 
 Whilst anti-viral TLRs and RLRs are well recognised for their role in inducing 7 
type I and type III IFNs, more recently RNA polymerase III (RNA pol III), an enzyme 8 
involved in the transcription of non-coding RNA, was reported to act as an anti-viral 9 
PRR by regulating type I IFN induction through generation of a RIG-I ligand 31,32. 10 
RNA pol III is able to transcribe AT-rich dsDNA into the 5’ppp-dsRNA format required 11 
for recognition by RIG-I and subsequent IFN induction 32. Interestingly, an 12 
autoantigen associated with systemic autoimmune disease, La/SSB (La), binds to 13 
RNA pol III transcripts and stabilises newly-synthesised RNAs 33-38. In addition to its 14 
interaction with a large variety of newly-formed RNAs, La binds a number of virus-15 
encoded RNAs, such as adenovirus VA RNA I and VA RNA II, EBV EBER 1 & 2 16 
RNA, and leader RNA of negative strand RNA viruses 39-42. Because La can interact 17 
with viral RNA, studies have sought to clarify its role in anti-viral immunity. Some 18 
studies proposed that La is manipulated by viruses in an attempt to block the anti-19 
viral response, which it reportedly achieves by binding and sequestering the dsRNA 20 
ligand for RIG-I, thus preventing activation of the pathway 43-45. On the other hand, 21 
La was also shown to promote an anti-viral response to flock house virus (FHV), 22 
although the mechanism involved was unclear 46. Thus the role of La in regulating 23 
anti-viral immune responses is not well understood.  24 
 Our work described herein demonstrates a novel positive role for La in 25 
regulating type I and type III IFN responses downstream of Sendai virus infection. 26 
Our results show that knockdown of La severely impairs the ability of cells to mount 27 
an anti-viral response to Sendai virus infection, resulting in enhanced infectivity, as a 28 
result of reduced type I and III IFN production. We observed that La bound RIG-I in a 29 
ligand-inducible manner and that the CARD domains of RIG-I and RNA-binding 30 
domain of La are required for this interaction. The association between La and RIG-I 31 
promotes the interaction of RIG-I with dsRNA, thereby enhancing RIG-I-driven type I 32 
and type III IFN induction. Thus, La is required for an optimum IFN response to 33 
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Sendai virus infection by binding to the anti-viral RIG-I receptor and promoting its 1 
interaction with its cognate ligand. 2 
 3 
 4 
  5 
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Results 1 
La depletion results in enhanced Sendai virus infection efficiency and 2 
decreased Type I and Type III Interferon responses  3 
Sendai virus (SeV) strains are enveloped paramyxoviruses with single-stranded, 4 
non-segmented, negative sense RNA genomes. SeV strains may vary significantly in 5 
their degrees of virulence. A number of virulence factors have been mapped to either 6 
structural proteins associated with differential virus attachment and entry into host 7 
cells, or non-structural proteins implicated in immune modulation that includes 8 
antagonism of interferon signalling 47-50. This study utilized a recombinant SeV 9 
expressing eGFP (rSeV/eGFP) and SeV Cantell strain, both capable of inducing type 10 
III IFN responses, while only the Cantell strain induces an additional robust type I 11 
IFN response 51,52. Evidence suggests that this differential induction of type I IFN is 12 
due to the presence of defective-interfering (DI) particles in the Cantell strain 53,54. 13 
To investigate the effect La knockdown on Sendai infectivity, HEK 293T cells 14 
infected with rSeV/eGFP and transfected with either a La-specific or scrambled 15 
shRNA were evaluated by UV microscopy, using areas of comparable monolayer 16 
confluency for image analyses (Figure 1). Supplemental Figure 1 demonstrates 17 
successful La depletion in HEK 293T cells, both at gene (Supplemental Figure 1a & 18 
b) and protein (Supplemental Figure 1c & d) levels, validating the La shRNA 19 
construct used throughout this work.  Analysis of fluorescence (using Image J 20 
software) demonstrated higher eGFP coverage following rSeV/eGFP infection in 21 
cells depleted of La compared with those transfected with the scrambled control, 22 
suggesting that knockdown of La enhanced viral infectivity (Figure 1a and b). 23 
Importantly, the increased eGFP coverage seen in La-depleted monolayers was 24 
reflected in an increase in viral titres released from these cells, compared with 25 
control cells (Figure 1c). As La has been published to be involved in a number of 26 
cellular processes, including RNAi processing, the viability of cells transfected with 27 
scrambled or La shRNA was compared in order to ensure that La knockdown did not 28 
affect cell viability. As shown in Figure 1d, cell viability was equivalent across the 2 29 
different experimental conditions. 30 
We next investigated the effect of La knockdown in HEK 293T cells on type I 31 
and type III IFN induction by quantitative PCR (qPCR) following rSeV/eGFP or SeV 32 
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Cantell infection. As stated above, rSeV/eGFP induced a strong type III IFN 1 
response but no type I IFN, whereas the SeV Cantell induced a robust type I IFN 2 
response in addition to type III IFNs 51,52. La knockdown resulted in significant 3 
reduction of both IFN-β and IFN-λ1 mRNA levels following SeV Cantell infection 4 
(Figure 2a and b), whereas a reduction in only IFN-λ1 expression was observed in 5 
La-depleted cells following infection with rSeV/eGFP, albeit at the later time point of 6 
48 hours post-infection (hpi) (Figure 2e and f). Importantly, La knockdown had no 7 
effect on housekeeping gene expression as shown in supplemental Figure 1e. 8 
Interestingly, expression of CXCL-10 (IP-10) was significantly attenuated by La 9 
depletion following infection with both SeV strains, compared with scrambled 10 
controls (Figure 2d and h). CXCL-11 was only impaired in La-depleted cells following 11 
Cantell infection (Figure 2c and g), suggesting that CXCL-11 induction is specifically 12 
regulated by La in the context of a type I IFN response. In contrast, the induction of 13 
CXCL-11 in response to rSeV/eGFP was poor, with La depletion having no effect on 14 
the cells’ ability to mount a response. 15 
Analysis of cytokine release following SeV infection demonstrated that CCL-5 16 
(RANTES, a type I and III-regulated chemokine) production was impaired following 17 
SeV Cantell infection in La-depleted cells (Figure 3a). Unsurprisingly, given that ISG 18 
expression was only induced at mRNA level following 48 hpi, no CCL-5 release was 19 
detected following infection with rSeV/eGFP strain across the 48 hour time course of 20 
infection, nor was any significant difference observed in La-depleted cells, compared 21 
with scrambled controls (Figure 3c). IFN-λ1 release was completely abrogated in La-22 
depleted cells, compared with controls, following infection with either SeV strain, 23 
further supporting our findings suggesting that La is crucial for the IFN response 24 
downstream of viral infection (Figure 3b and d). Assessing the effect of La 25 
knockdown on proinflammatory cytokine production in response to SeV Cantell 26 
infection demonstrated that La knockdown had little or no effect on the ability of the 27 
Cantell strain to induce IL-8, IL-6 or TNF-α (Figure 3e-g). Importantly, our results 28 
demonstrate not only that La positively regulates type I IFN responses downstream 29 
of SeV infection, but that it also has a novel role in promoting type III I IFN induction 30 
downstream of SeV infection.  31 
La enhances RIG-I binding to RNA ligand via direct interaction with the CARD-32 
domain of RIG-I 33 
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SeV Cantell has been reported to rely entirely on RIG-I to elicit an anti-viral immune 1 
response 55. Having demonstrated that La is required for type I and III IFN production 2 
in response to SeV challenge, and given its ability to bind RNA, we hypothesised 3 
that La may directly regulate RIG-I activation through regulation of RNA binding. To 4 
test this hypothesis, HEK 293T cells were transfected with FLAG-tagged RIG-I and 5 
increasing concentrations of La from 0-2 μg. Cell lysates were incubated with 1 μg 6 
biotin-labelled poly(I:C), and poly(I:C)-binding proteins were subsequently isolated. 7 
The ability of RIG-I to bind poly(I:C) was determined by western blotting using anti-8 
FLAG antibody. As Figure 4a shows, increasing concentrations of La enhanced the 9 
ability of RIG-I to bind poly(I:C). A faint lower band on the gel (corresponding to La) 10 
indicates, as would be expected from previous reports, that La was also capable of 11 
direct interaction with the RNA ligand. The lower panel of Figure 4a demonstrates 12 
total RIG-I and La expression in the lysates; endogenous La can be observed 13 
strongly in the lane without FLAG-tagged La overexpressed, due to blotting with anti-14 
La antibody. However, transfection with increasing concentrations of La (lanes 2-5) 15 
dose-dependently increases expression, as expected. Full blots as well as statistical 16 
analysis of corresponding optical densitometry across three individual experiments 17 
are shown in Supplemental Figure 2. 18 
Having observed enhanced binding between RIG-I and its RNA ligand in the 19 
presence of over-expressed La, we hypothesised that La may achieve this through 20 
direct binding to RIG-I. Co-immunoprecipitation studies demonstrated an inducible 21 
interaction between La and RIG-I following stimulation of RIG-I overexpressing HEK 22 
293T cells with the RIG-I agonist, 5’ppp-dsRNA (Figure 4b, Supplemental Figure 3). 23 
This inducible interaction was statistically significant across three independent 24 
experiments (Supplemental Figure 3d). In addition, HeLa cells over-expressing GFP-25 
La and flag-tagged RIG-I were stimulated with 5’ppp-dsRNA, which induces La 26 
translocation from the nucleus to the cytoplasm where it can co-localise and interact 27 
with RIG-I (Figure 4c). Additional confocal images demonstrating this pattern are 28 
shown in Supplemental Figure 4 and overlap coefficients for each image are given in 29 
Supplemental Table S4.1. The translocation of La from the nucleus to the cytoplasm 30 
is consistent with data from previous studies that demonstrate similar translocation of 31 
La following viral infection 44,45,56. In addition, cells depleted of La had a reduced 32 
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response to 5’ppp-dsRNA in their ability to induce IFN-β, confirming the ability of La 1 
to directly promote RIG-I induced IFN-β expression (Supplemental Figure 3c). 2 
In order to determine the domains responsible for this interaction, either full-3 
length or N-terminal-only (aa 1-204) His-tagged recombinant La was incubated with 4 
lysates from HEK 293T cells over-expressing full-length RIG-I, the CARD domain-5 
only of RIG-I, or the helicase domain-only of RIG-I. Potential interactions were 6 
analysed by western blotting. As Figure 4d (upper panel) demonstrates, an 7 
interaction was observed between full-length La and full-length RIG-I, as expected, 8 
but also with the RIG-I deletion mutant expressing only the CARDs. No interaction 9 
was observed with helicase-only mutant of RIG-I. This indicates that the activatory 10 
CARD domains (spanning amino acids 1-284) of RIG-I are necessary and sufficient 11 
for the interaction between La and RIG-I to occur. Further analysis demonstrated 12 
that the N-terminal but not the C-terminal domain of La is required for interaction with 13 
both full length and CARD domains of RIG-I (Figure 4d, lower panel).  14 
Collectively, our results indicate a novel role for La as a positive regulator of type 15 
I and type III IFN production in response to SeV infection. We demonstrate that the 16 
mechanism of this regulation occurs through a direct interaction between La and 17 
RIG-I, which promotes RIG-I binding to its cognate ligand. Our findings not only 18 
contribute to the understanding of molecular mechanisms behind RIG-I-mediated 19 
regulation of IFN induction, but also provide valuable insight into the potential that 20 
dysregulation of La activity may contribute to over-activation of RIG-I and hence 21 
dysregulated IFN production, as observed in autoimmune diseases such as SLE.  22 
  23 
  24 
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Discussion: 1 
The induction of IFN expression is a crucially important part of the innate anti-viral 2 
immune response, not only for destruction of viral RNA and limitation of viral spread, 3 
but also for activation of adaptive immunity and selective killing of virally-infected 4 
host cells. With this work we have demonstrated a novel interaction between La and 5 
RIG-I, which results in enhanced RIG-I-RNA association. Knockdown of La resulted 6 
in increased Sendai viral infection efficiency, decreased IFN-β, IFN-λ1 and ISG 7 
mRNA expression and attenuated CCL-5 and IFN-λ1 release, compared with control 8 
cells. Overall, these findings highlight an essential and novel role for La in mediating 9 
optimal type I and type III IFN responses following viral challenge in order to protect 10 
the host by both limiting viral replication and promoting the clearance of the 11 
pathogen. 12 
Type I IFNs are the first line of defence against most types of viral infection, 13 
including the murine pathogen, SeV (DI+). They induce an anti-viral state in host 14 
cells. This is achieved by JAK/STAT pathway-mediated activation of interferon-15 
stimulated genes (ISGs), such as RIG-I, CXCL-10, CXCL-11, OAS1 and OAS2 57. 16 
Our findings demonstrated a significant decrease in the induction of IFN-β, CXCL-10, 17 
and CXCL-11 following SeV infection upon depletion of La. While type III IFNs are 18 
structurally and genetically distinctive from type I IFNs and act through a separate 19 
receptor system, they have similar mechanisms of induction, signal transduction and 20 
biological function 26,58. SeV is a potent inducer of type III IFN responses 27,59. Our 21 
study identifies La as a novel positive regulator of IFN-λ1 induction downstream of 22 
SeV infection. Collectively our results indicate an important role for La in inhibiting 23 
SeV replication by promoting both type I (as seen following Cantell infection) and 24 
type III (as seen following Cantell and rSeV/eGFP) IFN responses.  25 
 RIG-I is central to the regulation of both type I and type III IFN production as it 26 
is responsible for detection of SeV infection within cells. Regarding regulation of 27 
RIG-I activity, a number of proteins have been identified to play a role through post-28 
translational modifications. For example, TRIM25 and Riplet/RNF135/REUL induce 29 
K63-linked ubiquitination within the CARD domains of RIG-I following viral infection, 30 
a modification which is necessary for interaction with IPS-1 60-62. In addition, CK2-31 
mediated phosphorylation of RIG-I at Thr 770 and Ser 854 inhibits the anti-viral 32 
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response to both hepatitis C virus and SeV and renders RIG-I inactive 63. This 1 
prevents TRIM25-mediated ubiquitination of RIG-I, thereby negatively regulating the 2 
IFN response 60. With this work, we have identified a novel function for the 3 
autoantigen La in enhancement of anti-viral responses. Specifically, it binds directly 4 
to the RIG-I receptor in an inducible manner and strengthens RIG-I binding to its 5 
RNA ligand, making it unique in its mechanism of action from other known RIG-I 6 
regulators, such as TRIM25 and CK2. Thus La positively regulates type I and type III 7 
IFN responses by augmenting stable RNA-RIG-I complex formation, which results in 8 
robust pathway activation. As RIG-I can also drive inflammatory gene expression 9 
through interaction with a IPS-1-CARD9-Bcl-10 complex and activation of NFκB 64, it 10 
would appear that the interaction between La and RIG-I is able to enhance the IFN-β 11 
response (presumably via enhancing interaction of IPS-1 with TBK-1) possibly 12 
independent of the ability of RIG-I to drive NFκB activation. This is supported by the 13 
fact that La knockdown has no effect on inflammatory gene expression downstream 14 
of RIG-I interaction whereas IFN-β expression is severely reduced.  15 
Regarding a potential role for La in regulating assembly of RNA-binding complexes, 16 
Liu and colleagues 46 demonstrated a role for La in RNAi processing. They reported 17 
that La associated with Ago2 of the RISC complex in an RNA-dependent manner, 18 
thereby promoting RISC complex catalysis and RNAi processing. This finding is 19 
consistent with our data which show that La augments RIG-I binding to poly I.C. 20 
Importantly, deletion of the RNA-binding domain of La blocks interaction with RIG-I, 21 
underlining the RNA-binding role of La in driving RIG-I activity. In keeping with our 22 
findings that La is a positive regulator of viral-induced type I IFN, Liu et al showed 23 
that La could promote the anti-viral response to flock house virus (FHV) in 24 
Drosophilia S2 cells. Indeed, La depletion resulted in increased FHV infectivity, 25 
which supports our findings that La promotes anti-viral responses to Sendai virus in 26 
HEK 293T cells. In contrast, Bitko and colleagues demonstrated enhanced IFN-β 27 
mRNA levels and decreased viral titres upon siRNA depletion of La 43. In addition, 28 
Domitrovich et al. argued a role for La as a negative regulator of IFN production in 29 
the context of HCV replication, based on a 63-67% reduction in RNA replication in 30 
the absence of La in Huh7 cells and increased IFN-β mRNA 10 hours post-RSV 31 
infection in the absence of La 44. However, similar to our findings, both of these 32 
studies also observed an overall decrease in IFN-β production 24 hours post-33 
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infection in La-depleted cells, suggesting that La may play a dual role in regulating 1 
anti-viral responses. Indeed, La may play a role in maintaining homeostasis in cells 2 
with respect to IFN-β production, as evidenced by the enhanced IFN-β expression in 3 
unstimulated cells depleted of La (Supplementary Figure 3c), whereas when RIG-I is 4 
activated, depletion of La results in substantial reduction in IFN-β production. This 5 
indicates that the loss of La may somehow disrupt homeostatic mechanisms to 6 
maintain appropriate IFN-β levels or indeed may inhibit viral-specific evasion 7 
mechanisms. For example, the RSV-derived NS2 protein binds to RIG-I and blocks 8 
its interaction with IPS-1, thereby preventing IRF-3 activation 65,66. Thus the loss of 9 
La may disrupt the negative function of NS2 on this system, thereby contributing to 10 
the enhanced IFN-β observed in similar studies. Extensive studies would be required 11 
to address these questions, which are outside the scope of this manuscript.  12 
With this work, we identify role for La in regulating IFN responses by promoting 13 
the RIG-I-mediated anti-viral response through direct association with RIG-I and 14 
enhancing RIG-I binding to its viral agonist. Importantly, our study is the first to 15 
assess the role for La in regulating type III IFN responses, with all previous studies 16 
focusing on type I IFN only. SeV infection experiments support these findings, with 17 
depletion of La resulting in increased viral infectivity and decreased type I and type 18 
III IFN responses, compared with controls. These findings highlight an important and 19 
novel role for La in the promotion of optimal type I and type III IFN responses 20 
following SeV challenge, serving to protect the host through limiting viral replication. 21 
 22 
  23 
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Methods 1 
Materials 2 
The SW5 monoclonal La antibody was generated by Professor Michael Bachmann 3 
at the Technical University of Dresden and was a kind gift from Dr. JS Maier-Moore 4 
67. All flag-tagged RIG-I plasmid constructs were a kind gift from Dr. Kate Fitzgerald 5 
(UMASS Med School, Worcester, MA). The GFP-tagged La construct was a gift from 6 
Dr. Karl Albert Brokstad (University of Bergen, Germany). Monoclonal M2 Flag 7 
antibody was purchased from Santa Cruz, pcDNA3.1 empty vector control from 8 
Invitrogen and biotin-labelled poly(I:C) from Cayla-Invivogen. A Mission® shRNA 9 
construct specific to human La, as well as a scrambled control, were purchased from 10 
Sigma. 11 
 12 
Cell Culture  13 
HEK 293T and HeLa cell lines were cultured in Dulbecco’s Modified Essential 14 
Medium (DMEM) containing stable 2 mM L-glutamine, 10% (v/v) foetal calf serum 15 
(FCS), 100 units/ml Penicillin, 100 μg/ml Streptomycin and 100 μg/ml gentamicin. 16 
LLC-MK2 cells (ECACC 85062804) were grown in minimum Eagle’s medium (MEM) 17 
containing 40 g/ml non-essential amino acids and supplemented with 10% heat 18 
inactivated FCS, 2 mM L-glutamine, 2 mg/ml sodium carbonate, 100 g/ml gentamicin 19 
and 1.25 mg/ml Fungizone. Cells were maintained at 37°C in a humidified 20 
atmosphere of 5% CO2.  21 
 22 
La Knockdown 23 
HEK 293T cells were seeded at 5 × 104 cells per ml and transfected the following 24 
day with 500 ng of scrambled or La-specific shRNA (Sigma). Following 48 hr, cells 25 
were washed with PBS prior to viral infection as detailed below. 26 
 27 
Viral Infection 28 
The rescue and characterisation of recombinant Sendai virus expressing eGFP 29 
(rSeV/eGFP) was previously described 68. The SeV Cantell strain, a wild type strain 30 
containing defective interfering particles, comes originally from Charles River 31 
Laboratories. Media was discarded and replaced with fresh pre-warmed DMEM 32 
supplemented with antibiotic only (no FCS), in order to limit cell growth. Cells were 33 
15 
 
then infected with either rSeV/eGFP or SeV Cantell at a multiplicity of infection (MOI) 1 
of 0.1 or 10, as indicated in figure legends. One hour post-infection, inocula were 2 
removed by discarding media and replaced with DMEM supplemented with antibiotic 3 
and 1% FCS to ensure cell survival while maintaining limited growth. At indicated 4 
time points, media was carefully removed and retained for subsequent cytokine 5 
analysis, cells were gently re-suspended in ice-cold PBS and centrifugation was 6 
carried out at 400×g for 5 min to pellet cells for subsequent analysis. Cells were then 7 
re-suspended in Trizol reagent for gene expression analysis or SDS sample buffer 8 
supplemented for protein expression analysis. 9 
 10 
SeV titrations 11 
For SeV/eGFP, a 1:10 dilution series of the sample was added to LLC-MK2 cells in 12 
MEM 1% FBS. At 24 hpi fluorescent foci were counted. The titer is calculated as 13 
fluorescent forming units (FFU) by multiplying the average number of foci by the 14 
dilution factor at a given dilution. The dilution at which the foci were counted is equal 15 
to the inverse of the exponent of the final FFU. The titer of SeV Cantell stock was 16 
determined by plaque assay as previously described 69. 17 
 18 
Real-time polymerase chain reaction (qPCR) 19 
RNA was extracted from cell cultures using Trizol™ (Sigma) and reverse transcribed 20 
to complementary DNA using the GoScript Reverse Transcription kit (Promega), as 21 
per manufacturer’s instructions. Real-time quantitative PCR investigating gene 22 
expression was performed using primers listed in Table 1, with SYBR Green Taq 23 
ReadyMix (Sigma) according to manufacturer’s recommendations. Data were 24 
analyzed using an ABI Prism 7900 system (Applied Biosystems) and were 25 
normalized to 18s RNA. Real-time PCR data were analyzed using the 2-∆∆ct method 26 
70. 27 
 28 
Western blotting 29 
16 
 
To prepare whole cell lysates, cells were lysed in SDS buffer (250 mM Tris-HCl, pH 1 
6.8, 10% SDS, 0.5% Bromophenol blue, 50% Glycerol, 50 nM DTT) and boiled at 2 
95°C for 10 min. Equal quantities of whole cell lysates were resolved by 3 
electrophoresis on a denaturing SDS–polyacrylamide gel according to the method of 4 
Laemmli 71 and transferred to a nitrocellulose membrane. Following immunoblotting, 5 
the membrane was developed using enhanced chemiluminescent horse radish 6 
peroxidase (HRP) substrate (Millipore).  7 
 8 
Co-immunoprecipitation 9 
Cells were treated as described in the figure legends, lysed in EBC lysis buffer 10 
(Deionised water containing 50 mM Tris (pH 8.0), 150 mM NaCl, 1% Nonidet P40, 11 
0.5% (w/v) sodium deoxycholate and 0.1% SDS containing 1 mM Sodium 12 
orthovanadate (Na3VO4), 1 mM Phenylmethylsulfonylfluoride (PMSF), 1 mM 13 
Potassium fluoride (KF),) and incubated with SW5 anti-La antibody coupled to 14 
protein A sepharose beads. Thereafter, immune complexes were washed and re-15 
suspended in SDS sample buffer for western blot analysis. 16 
 17 
Recombinant protein pull-downs 18 
Following a gentle wash with ice-cold PBS, lysates were prepared by addition of 19 
EBC buffer. After sonication and centrifugation, the supernatant was incubated with 20 
50 μl Nickel agarose beads coupled to approximately 1 μg either full length (8A) or 21 
N-terminal truncated (7A) recombinant La (Dr. J. Maier-Moore), for 2 h on rotation at 22 
4°C. After incubation, nickel agarose was washed three times with EBC buffer by 23 
gentle inversion and centrifugation at 5,000 × g. Beads were then re-suspended in 24 
SDS sample buffer for western blot analysis. 25 
 26 
Enzyme-linked Immunosorbance Assay (ELISA)  27 
17 
 
ELISAs were carried out using DuoSet® ELISA Development Kit for human CCL-5 1 
(Rantes) or human IFN-λ1 (IL-29) (eBioscience) as per the manufacturer’s 2 
instructions. 3 
 4 
RNA Immunoprecipitation  5 
Cells were seeded and transfected as indicated in figure legends.  Cells were lysed 6 
for 20 min at 4°C on rotation in freshly prepared sterile RNA Immunoprecipitation 7 
(RIP) buffer (150 mM KCl, 25 mM Tris pH 7.4, 5 mM EDTA, 0.5 mM DTT, 0.5% NP-8 
40) supplemented with protease inhibitors and SUPERase RNAse inhibitor (Sigma). 9 
Samples were sonicated for 15 sec, cell debris was pelleted by centrifugation and 10 
cell supernatants were transferred to fresh tubes. One µg of biotin-labelled poly(I:C) 11 
(Invivogen) was added, followed by incubation at 4°C for 1-2 h. The samples were 12 
then added to 50 µl of pre-washed UltraLink NeutrAvidin beads (Pierce) and 13 
incubated for 1 h at 4°C. The resulting immune complexes were then washed with 14 
RIPA buffer and re-suspended in 30 µl SDS sample buffer, prior to western blot 15 
analysis. 16 
 17 
Immunofluorescence 18 
HeLa cells were seeded at 1 × 105/well on coverslips, transfected and stimulated as 19 
indicated in figure legends. Cells were fixed and permeabilised with 4% 20 
paraformaldehyde and 0.2% (v/v) Triton X-100 in PBS. After washing, cells were 21 
blocked in PBS with 1.2% (w/v) Fish Gelatin and 100 mM glycine and then incubated 22 
at 37°C for 1 h with the primary antibody of interest at 1:100 dilution in blocking 23 
buffer, followed by detection with the appropriate fluorescently labelled secondary 24 
antibody at 1:200 dilution. Cells were mounted and nuclei stained using ProLong® 25 
Gold anti-fade reagent with DAPI. Cells were imaged using the LSM 710 System 26 
(Carl Zeiss) and analysed for co-localisation using Zen 9 software. 27 
 28 
Statistical analysis 29 
18 
 
All data was analysed using GraphPad Prism (version 7) statistical software 1 
package, as specified. Statistical comparison between groups was carried out using 2 
tests described in figure legends. Data is graphically represented as mean +/- 3 
standard error of the mean (SEM). P values less than or equal to 0.05 were 4 
considered significant. 5 
 6 
Data Availability 7 
• No datasets were generated or analysed during the current study. 8 
• All data generated or analysed during this study are included in this published 9 
article (and its Supplementary files). 10 
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 Figure legends 4 
Figure 1: Depletion of La in HEK 293T results in an increase in Sendai viral 5 
infection efficiency. HEK 293T cells were transfected with 500 ng of La-specific or 6 
scrambled Mission® shRNA (Sigma) for 48 h. Cells were then infected with 7 
rSeV/eGFP at an MOI of 0.1. (a) GFP positivity was visualised using a Nikon Eclipse 8 
TE2000-U and a Hamamatsu ORCA ER camera. (b) % monolayer GFP-positive 9 
analysis was carried out using Image J software. (c) rSeV/eGFP titrations (FFU/mL) 10 
were carried out on LLC-MK2 cells. Areas under the curves were calculated and 11 
compared. Results are from two independent experiments carried out in duplicate. 12 
(d) 48h post transfection, a well from each condition (Scrambled or La) was 13 
trypsinised, following which a trypan blue cell count was performed to determine the 14 
number of viable cells prior to infection. Data shown is combined average cell counts 15 
from two independent experiments. 16 
 17 
Figure 2: IFN-β IFN-λ and ISG mRNA expression is attenuated in La-depleted 18 
cells following SeV infection. HEK 293T cells were transfected with 500 ng of 19 
either La-specific or scrambled Mission® shRNA (Sigma) for 48 h after which they 20 
were infected with SeV Cantell (a-d) or rSeV/eGFP (e-h) at an MOI of 10 and 21 
incubated for the indicated time points. IFN-β (a, e), IFN-λ1 (b, f), CXCL11 (c, g), 22 
CXCL10 (d, h) expression was determined by RT-qPCR. Data shown are a 23 
representative of three independent experiments in each case. *p<0.05, **p< 0.01, 24 
***p<0.001 and ***p<0.0001, as determined by unpaired t-test, comparing scrambled 25 
to La shRNA at each time point. 26 
 27 
Figure 3: CCL5 & IFN-λ1 release is decreased in La-depleted cells following 28 
SeV infection. HEK 293T cells were transfected with 500 ng of either La-specific or 29 
scrambled Mission® shRNA (Sigma) for 48 h after which they were infected with 30 
SeV Cantell (a-b) or rSeV/eGFP (c-d) at an MOI of 10. CCL5 (a, c) and IFN-λ1 (b, d) 31 
24 
 
cytokine release was determined by ELISA. IL-8 (e), IL-6 (f) and TNF-α (g) was 1 
measured from cells supernatants using a multi-plex human pro-inflammatory 7-spot 2 
assay (MSD). Data shown is the combined average of three independent 3 
experiments. *p<0.05, **p<0.01 and ****p<0.0001, as determined by unpaired t-tests, 4 
comparing scrambled to La shRNA at each time point. 5 
 6 
Figure 4: La enhances RIG-I binding to RNA ligand and interacts with RIG-I 7 
following 5’ppp-dsRNA stimulation. (a) HEK 293T cells were transfected with 4 μg 8 
EV or 2 μg FLAG-tagged RIG-I with increasing FLAG-tagged La, as indicated. 9 
Analysis of the ability of FLAG-tagged La or RIG-I to bind biotinylated poly(I:C) was 10 
assessed by western blotting with anti-FLAG antibody. Expression of FLAG-tagged 11 
or RIG-I constructs in whole cell lysates was determined by western blotting with 12 
either anti-La or anti-RIG-I antibodies, as appropriate. (b) HEK 293T cells were 13 
transfected as indicated and stimulated for 1, 3, or 6 h with 1 μg 5’ppp-dsRNA 14 
(Invivogen). Following immunoprecipitation of La-containing complexes with a La-15 
specific antibody, the ability of over-expressed RIG-I to interact with endogenous La 16 
was determined by western blotting using anti-FLAG antibody. (c) HeLa cells were 17 
seeded on UV-irradiated coverslips, transfected with 2 μg of GFP-tagged La and 2 18 
μg FLAG-tagged RIG-I, following which they were stimulated with 1 μg 5’ppp-dsRNA 19 
for 6 h. Immunostaining with anti-RIG-I antibody indicates that La and RIG-I co-20 
localise following stimulation with 5’ppp-dsRNA. Both images are at 63X 21 
magnification. (d) Recombinant La was incubated with lysates prepared from HEK 22 
293T cells overexpressing FLAG-tagged RIG-I, FLAG-tagged RIG-I-CARD, or 23 
FLAG-tagged RIG-I-Helicase (Heli), as indicated. The ability of RIG-I and La to 24 
interact was analysed by western blotting. In all cases images are representative of 25 
three independent experiments.  26 
 27 
Table 1: Human primers used in this study; 28 
Primer Name Primer Sequence Product Size(bp)
La sense GAAGGAGAGGTGGAAAAAG 372 
La anti-sense AAGCCCCGCAAACAAAAG  
IFN-β sense CTAGCACTGGCTGGAATGAGA 217 
25 
 
IFN-β anti-sense CTGACTATGGTCCAGGCACA  
18S sense TTGACGGAAGGGCACCACCA 131 
18S anti-sense GCACCACCACCCACGGAATCG  
IFN-λ1 sense GGACGCCTTGGAAGAGTCACT 84 
IFN-λ1 anti-sense AGAAGCCTCAGGTCCCAATTC  
CXCL-10 sense GGAAGCACTGCATCGATTTTG 519 
CXCL-10 anti-sense CAGAATCGAAGGCCATCAAGA  
CXCL-11 sense GCCTTGGCTGTGATATTGTGTG 686 
CXCL-11 anti-sense CACTTTCACTGCTTTTACCCCAG  
 1 
 2 




